EA201891597A2 - BISPECIFIC TO EGFR / C-Met ANTIBODIES - Google Patents
BISPECIFIC TO EGFR / C-Met ANTIBODIESInfo
- Publication number
- EA201891597A2 EA201891597A2 EA201891597A EA201891597A EA201891597A2 EA 201891597 A2 EA201891597 A2 EA 201891597A2 EA 201891597 A EA201891597 A EA 201891597A EA 201891597 A EA201891597 A EA 201891597A EA 201891597 A2 EA201891597 A2 EA 201891597A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- egfr
- receptor
- bispecific
- met antibodies
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Abstract
Изобретение касается биспецифических к EGFR и/или c-Met антител и способов получения и применения молекул. Рецептор эпидермального фактора роста (EGFR, ErbB1 или HERI) представляет собой трансмембранный гликопротеин типа I с массой 170 кДа, кодируемый протоонкогеном c-ErbB1. EGFR является членом семейства человеческих рецепторов эпидермальных факторов роста (HER), которые представляют собой рецепторные тирозинкиназы (RTK), включающим HER2 (ErbB2), HER3 (ErbB3) и HER4 (ErbB4). Сигнализация EGFR инициируется связыванием лигандов, за которым следует индукция конформационного изменения, гомодимеризация или гетеродимеризация рецептора с другими членами семейства ErbB.The invention relates to bispecific to EGFR and / or c-Met antibodies and methods for producing and using molecules. The epidermal growth factor receptor (EGFR, ErbB1 or HERI) is a type I 170 kDa transmembrane glycoprotein encoded by the c-ErbB1 proto-oncogene. EGFR is a member of the epidermal growth factor (HER) human receptor family, which are receptor tyrosine kinases (RTKs), including HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). EGFR signaling is initiated by ligand binding, followed by induction of a conformational change, homodimerization or heterodimerization of the receptor with other members of the ErbB family.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361892797P | 2013-10-18 | 2013-10-18 |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201891597A2 true EA201891597A2 (en) | 2018-12-28 |
EA201891597A3 EA201891597A3 (en) | 2019-03-29 |
EA039356B1 EA039356B1 (en) | 2022-01-18 |
Family
ID=80685590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891597A EA039356B1 (en) | 2013-10-18 | 2013-11-21 | BISPECIFIC EGFR/c-Met ANTIBODIES |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA039356B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
KR20110124368A (en) * | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | Bispecific anti-erbb-2/anti-c-met antibodies |
CA2791863C (en) * | 2010-03-10 | 2022-06-21 | Genmab A/S | Monoclonal antibodies against c-met |
-
2013
- 2013-11-21 EA EA201891597A patent/EA039356B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA039356B1 (en) | 2022-01-18 |
EA201891597A3 (en) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590985A1 (en) | BISPECIFIC TO EGFR / c-Met ANTIBODIES | |
PH12020550055A1 (en) | Antibodies that bind egfr and cmet | |
MX2012011718A (en) | Anti-erbb3 antibodies. | |
MX2014014162A (en) | Multispecific antibodies. | |
WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
CY1119591T1 (en) | SPECIAL CONNECTION PROTEINS AND THEIR USES | |
NZ740980A (en) | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use | |
NZ743881A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
CY1122456T1 (en) | MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER | |
EA201390472A1 (en) | NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES | |
MX358728B (en) | Humanized pan-her antibody compositions. | |
AR094403A1 (en) | ANTI-HER3 ANTIBODY COMBINATION THERAPY | |
JP2012017341A5 (en) | ||
UA110049C2 (en) | Osteoarthritis treatment with immunoglobulin binding protein with double variable domain linking IL-1α and IL-1β | |
AR088671A1 (en) | METHODS TO INHIBIT TUMOR GROWTH ANTAGONIZING THE IL-6 RECEPTOR | |
EA201492163A1 (en) | HUMANIZED ANTIBODIES TO TRKA, CONTAINING AMINO ACID SUBSTITUTES | |
PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
MX2016014416A (en) | Anti-her3 antibodies binding to the beta-hairpin of her3. | |
EA201891597A2 (en) | BISPECIFIC TO EGFR / C-Met ANTIBODIES | |
TN2015000557A1 (en) | Divalent vaccine compositions and the use thereof for treating tumours | |
EA201590413A1 (en) | COMPOUNDS OF ACRYLAMIDE AS HYSTAMINE H RECEPTOR LIGANDS | |
MX2016014726A (en) | Her1 antigen binding proteins binding to the beta-hairpin of her1. | |
BR112021022828A2 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors | |
Neustroeva | PSYCHOLOGICAL SCIENCES | |
Hobbs | The basis of ErbB4 ligand specificity |